Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Pugs who wrote (23831)	6/5/1998 9:58:00 AM
From: Leman	Read Replies (1) \| Respond to of 34592

Gene Logic Celebrates Opening of Corporate Headquarters in Gaithersburg GAITHERSBURG, Md.--(BUSINESS WIRE)--June 5, 1998--Gene Logic Inc. (Nasdaq: GLGC - news) announced today that it is holding an Open House to celebrate the Company's newly established Corporate Headquarters in Gaithersburg, Maryland. Today's Open House is scheduled to commence at 2:30 p.m. (EST) and will feature presentations by Congresswoman Connie Morella of the 8th District in Maryland, Alan G. Walton, Ph.D., D.Sc., General Partner, Oxford Bioscience Partners, Michael J. Brennan, M.D., Ph.D., President and CEO of Gene Logic Inc., George Griffin, Special Assistant to the County Executive, Montgomery County and Sidney A. Katz, Councilman of Gaithersburg. The new purpose-built facility is approximately 50,000 square feet with the second floor dedicated exclusively to laboratory space. The first floor is comprised of bioinformatics and administrative offices. Gene Logic also has a Bioinformatics System Division in Berkeley, California. The Company currently employs approximately 110 people. ''We decided on the 270 technology corridor because it is one of the world's leading centers for genomics and bioinformatics business.'' said Mark D. Gessler, Senior Vice President Corporate Development and Chief Financial Officer. GENE LOGIC combines powerful genomics technologies and bioinformatics expertise to accelerate the discovery and development of new drugs. The Company provides its pharmaceutical company partners with products designed to reduce the time, cost and risk associated with drug discovery and development. These include proprietary genomic databases of gene expression for new drug target discovery and development, a novel screening technology for identifying new drug leads, and a comprehensive bioinformatics system for analyzing, managing and integrating biological information into the drug discovery process. Gene Logic has established strategic alliances with N.V. Organon, a pharmaceutical business unit of Akzo Nobel, Procter & Gamble Pharmaceuticals, Inc., Japan Tobacco Inc. and SmithKline Beecham.